AAA February 2016 – Page 14

Galera advances series B to $42m

US-based biotechnology company Galera Therapeutics boosted its series B round, backed by investors including pharmaceutical companies Novartis and Novo, to $42m on Wednesday following a $5m extension from investment firm Enso Ventures. The round’s first tranche, closed in October 2015, was led by Novo subsidiary Novo Ventures. Novartis participated in the first tranche through its… Continue reading Galera advances series B to $42m